Market Place
Sourcing Support
Hookipa Pharma to Present Eseba-vec Data at SITC 2024
31 Oct 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Doses Patients with Eseba-vec for Cancer
30 Oct 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
24 Sep 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Board of Directors Changes
30 Aug 2024 //
GLOBENEWSWIRE
Hookipa Pharma To Participate In H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
22 Jul 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
08 Jul 2024 //
GLOBENEWSWIRE
Hookipa Doses First Person In HB-500 HIV Treatment Trial
01 Jul 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma: Updated Phase 2 Oncology Data At ASCO 2024 Meeting
04 Jun 2024 //
GLOBENEWSWIRE
HOOKIPA To Host Call On HB-200 Data At ASCO 2024
30 May 2024 //
GLOBENEWSWIRE
Hookipa Positive Clinical Data: To Be Presented At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Q1 2024 Financials And Business Highlights
09 May 2024 //
GLOBENEWSWIRE
HOOKIPA Announces Pivotal Ph2/3 Trial Design For HB-200 + Pembrolizumab
25 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA`s HB-700 IND Cleared for KRAS-Mutant Cancers
24 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
16 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Provides Update on Business Priorities
29 Jan 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer
16 Jan 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
21 Dec 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces FDA Clearance of its Investigational NDA for HB-500
20 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200
03 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200
22 Oct 2023 //
GLOBENEWSWIRE
HOOKIPA announces publication of data of HBV vaccine developed with Gilead
18 Oct 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Rule 5635(c)(4)
12 Sep 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to participate in upcoming investor conferences in September
06 Sep 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Rule 5635(c)(4)
10 Jun 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200
31 May 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Pricing of $50.0 Million Public Offering of Common Stock
31 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
HOOKIPA doses first patient in trial of HB-400 for chronic hepatitis B
10 May 2023 //
CLINICAL TRIALS ARENA
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400
09 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report 1Q 2023 FYR & Recent Business Highlights May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
04 May 2023 //
GLOBENEWSWIRE
HOOKIPA to Present a Trial in Progress Prostate Cancer PH 1/2 Trial at ASCO
26 Apr 2023 //
GLOBENEWSWIRE
HOOKIPA to Participate in the Van Lanschot Kempen Life Sciences Conference
19 Apr 2023 //
GLOBENEWSWIRE
HOOKIPA Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
14 Apr 2023 //
GLOBENEWSWIRE
Immunome stops Covid-19 work; Hookipa drops CMV vaccine
16 Mar 2023 //
ENDPTS
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Hookipa halts spending on CMV vaccine after seeing phase 2 data
15 Mar 2023 //
FIERCE BIOTECH
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
13 Mar 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
HOOKIPA Achieves $10 Million Milestone Payment for KRAS-Mutated Cancers
13 Feb 2023 //
GLOBENEWSWIRE
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
HOOKIPA Achieves $5M Milestone Payment from Gilead for Hepatitis B Vaccine
04 Jan 2023 //
GLOBENEWSWIRE
HOOKIPA Appoints Katia Schlienger as CMO & Malte Peters to Board of Directors
15 Dec 2022 //
GLOBENEWSWIRE
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
30 Nov 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces 3Q 2022 Financial Results &Provides a Business Update
14 Nov 2022 //
GLOBENEWSWIRE
HOOKIPA to Report 3Q 2022 Financial Results & Corporate Updates on Nov 14, 2022
07 Nov 2022 //
GLOBENEWSWIRE
Roche and Hookipa Tie Up in KRAS Inhibitor Deal Valued at Potential $950M
21 Oct 2022 //
BIOSPACE
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07 Sep 2022 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2022 Rusult and Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
FDA accepts HOOKIPA`s Investigational NDA for HB-300
25 Jul 2022 //
GLOBENEWSWIRE
HOOKIPA Announces Executive Leadership Changes
21 Jun 2022 //
GLOBENEWSWIRE
